FDA antiviral advisory hearings on lamivudine (Epivir, 3TC), saquinavir (Invirase), stavudine (Zerit, d4T), November 6-8. Food and Drug Administration.
D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy*; D000998:Antiviral Agents / Q000627:therapeutic use*; D018791:CD4 Lymphocyte Count; D004352:Drug Resistance, Microbial; D017320:HIV Protease Inhibitors / Q000627:therapeutic use*; D006801:Humans; D007546:Isoquinolines / Q000627:therapeutic use*; D019259:Lamivudine; D011804:Quinolines / Q000627:therapeutic use*; D019258:Saquinavir; D018119:Stavudine / Q000627:therapeutic use*; D014481:United States; D014486:United States Food and Drug Administration; D016047:Zalcitabine / Q000031:analogs & derivatives / Q000627:therapeutic use*
D000998:Antiviral Agents; D017320:HIV Protease Inhibitors; D007546:Isoquinolines; D011804:Quinolines; D019259:Lamivudine; D016047:Zalcitabine; D018119:Stavudine; D019258:Saquinavir